Additionally, SP-A peptides presenting the CRD domain have been demonstrated to retain functional activity, as seen in previous studies by Kraft and Ledford.25 showing that SP-A peptides covering the CRD domain maintain bioactivity while successfully reducing airway hyperresponsiveness and inflammation in preclinical asthma models. The gene discussed is SFTPA2; the disease is asthma.